Alnylam Pharmaceuticals (United States)
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Alnylam Pharmaceuticals (United States), United States, covering academic research published from 2003 to 2024. Read More.
Open Access Percentage
57%
Total
Publications
894
Total Open
Publications
514
Total
Citations
81K
Open Access
Percentage
57%
Total
Publications
894
Total Open
Publications
514
Total
Citations
81K
Breakdown
Publisher Open
18%
Both
29%
Other Platform Open
8%
Closed
45%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 37%
148
Hybrid 32%
130
No Guarantees 31%
123
Other Platform Open
Domain 74%
243
Institution 30%
99
Other Internet 16%
52
Public 5%
16
Preprint 0%
1
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 246 |
DOI | Other Internet | 45 |
DANS - Data Archiving and Networked Services | Institution | 20 |
DASH - Digital Access to Scholarship at Harvard | Institution | 18 |
Massachusetts Institute of Technology - DSpace@MIT | Institution | 16 |
Figshare | Public | 15 |
Unknown Repository | Other Internet | 8 |
Europe PMC | Domain | 8 |
Elsevier - Scopus | Institution | 8 |
University of Modena and Reggio Emilia - IRIS UNIMORE | Institution | 6 |